Table 3.

Analysis of annual BMD change in the proximal femur

Parameter	Univariate analysis			Multivariable regression analysis (full model)		Multivariable regression analysis (reduced model)
	t	95%CI	p	t	95%CI	t	95%CI
Female over 60 years old	−0.30	− 0.52~0.38	0.76	− 0.12	− 0.27~0.24
BMI	−0.85	− 0.10~0.04	0.40	0.26	− 0.07~0.09
HbA1c (NGSP)	−0.90	− 0.67~0.25	0.36	−1.04	− 0.76~0.24	0.12	− 0.80~0.09
DAS28-ESR	−1.98	− 0.40~ − 0.001	0.049*	0.06	− 0.25~0.26
HAQ	0.48	− 0.38~0.63	0.63	− 0.81	− 0.56~0.24	−1.65	− 0.56~0.05
TSS	−0.26	− 0.66~0.51	0.31	− 0.40	− 0.003~0.002
MTX dose	−0.12	− 0.06~0.05	0.90	− 0.52	− 0.08~0.05
Steroid dose	0.52	− 0.06~0.11	0.60	0.05	− 0.09~0.10
bDMARD	1.89	− 0.02~0.92	0.06	0.35	− 0.15~0.42
Bisphosphonate	3.08	0.26~1.20	0.002*	3.53*	0.20~0.72	3.19*	0.15~0.62
Vitamin D	2.58	0.13~1.04	0.01*	2.72*	0.10~0.59	2.99*	0.12~0.58
RF	−0.60	− 0.004~0.002	0.55	1.07	− 0.001~0004
ACPA	−2.09	− 0.004~ − 0.0001	0.04*	− 2.34*	− 0.01~ − 0.001	− 2.42*	− 0.004~ − 0.0004
CRP	−4.03	− 0.49~ − 0.17	< 0.001*	− 0.71	− 0.36~0.17
TRACP-5b	−1.89	− 0.003~0.001	0.06	−1.00	− 0.003~0.001
Homocysteine	−1.81	− 0.12~ − 0.005	0.07	− 018	− 0.09~0.07
Uc-OC	0.66	− 0.06~0.04	0.65	0.68	− 0.04~0.09
BAP	−1.20	− 0.05~0.01	0.23	0.68	− 0.03~0.06
Urine pentosidine	−0.71	− 0.01~0.006	0.47	− 0.08	− 0.01~0.01

BMD bone mineral density, BMI body mass index, DAS28-ESR disease activity score in 28 joints-erythrocyte sedimentation rate, HAQ health assessment questionnaire, TSS total Sharp/van der Heijde score, MTX methotrexate, bDMARDs biological disease-modifiying anti-rheumatic drugs, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, CRP C-reactive protein, TRACP-5b tartrate-resistant acid phosphatase 5b, Uc-OC undercarboxylated osteocalcin, BAP bone-specific alkaline phosphatase

*p ≥ 0.05